Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448777 | 1.00 | THRB (0.39) | THRBHTTAXLSYKEGFR | |
| SCHEMBL3448610 | 0.94 | MAPK3 (0.40) | THRBHTTAXLSYKEGFR | |
| SCHEMBL3448626 | 0.94 | MAPK3 (0.40) | THRBHTTAXLSYKEGFR | |
| SCHEMBL13311805 | 0.91 | ZAP70 (0.38) | THRBAXLSYKEGFRBTK | |
| SCHEMBL13312476 | 0.91 | THRB (0.37) | THRBHTTAXLSYKEGFR | |
| SCHEMBL3450050 | 0.90 | SYK (0.45) | SYKRIPK2JAK2JAK3PTK2 | |
| SCHEMBL3450054 | 0.90 | SYK (0.45) | SYKRIPK2JAK2JAK3PTK2 | |
| SCHEMBL13311981 | 0.88 | THRB (0.35) | THRBHTTAXLSYKEGFR | |
| SCHEMBL3448160 | 0.88 | IDH1 (0.37) | THRBHTTAXLSYKEGFR | |
| SCHEMBL3448156 | 0.88 | IDH1 (0.37) | THRBHTTAXLSYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | THRB 3527/4885HTT 3861/4885AXL 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.